Financial news for NRX dated on 2016-05-02: 3 Companies Filed For Chapter 11 Bankruptcy Today

Financial news for NRX dated on 2016-05-02: Stocks Hitting 52-Week Lows

Financial news for NRX dated on 2016-05-02: NephroGenex Files For Bankruptcy Protection Under Chapter 11

Financial news for NRX dated on 2016-05-02: NephroGenex Shares Resumed Trade, Stock Down 70.5%

Financial news for NRX dated on 2016-05-02: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for NRX dated on 2016-05-02: NephroGenex Reports Commenced Voluntary Ch. 11 Proceeding, Looking to Begin Sale Process Under Section 363

Financial news for NRX dated on 2016-05-02: NephroGenex Shares Halted News Pending

Financial news for NRX dated on 2016-04-15: Rodman & Renshaw Assumes NephroGenex at Neutral

Financial news for NRX dated on 2016-04-08: H.C. Wainwright Downgrades NephroGenex to Neutral

Financial news for NRX dated on 2016-02-24: Here's Why NephroGenex Plunged 40% On Wednesday

Financial news for NRX dated on 2016-02-24: NephroGenex Says Paid Off \sim \$6.3M Term Loan, Has \sim \$11.5M in Cash, Cash Equivalents as of Feb. 23, 2016

Financial news for NRX dated on 2016-02-24: NephroGenex Board Will Explore Strategic Alternatives, Including Potential Reverse Merger Deal

Financial news for NRX dated on 2016-02-24: NephroGenex to Resume Trading @9:50 AM ET

Financial news for NRX dated on 2016-02-24: NephroGenex Offers Corporate Update: Will Pause Clinical Program for Product Candidate Oral Pyridorin for Treatment of Diabetic Nephropathy

Financial news for NRX dated on 2016-02-24: NephroGenex Shares Halted News Pending

Financial news for NRX dated on 2016-01-22: Mid-Morning Market Update: Markets Open Higher; General Electric Profit Beats Views

Financial news for NRX dated on 2016-01-21: NephroGenex Reports DSMB Recommendation To Continue Phase 3 Study Of Oral Pyridorin In Diabetic Nephropathy Without Modification

Financial news for NRX dated on 2016-01-05: NephroGenex Reports Formation of Scientific Advisory Board

Financial news for NRX dated on 2015-12-14: Thanks, FDA: NephroGenex Investors Rejoice After New Clearance

Financial news for NRX dated on 2015-12-14: NephroGenex Reports FDA Clearance of IND Application for Clinical Study of IV Pyridorin

Financial news for NRX dated on 2015-11-30: S-3 from NephroGenex Shows Registration for $\sim 10.245 M$ Share Common Stock Offering via Selling Holders

Financial news for NRX dated on 2015-11-12: Morning Market Losers

Financial news for NRX dated on 2015-11-11: NephroGenex Reports Q3 EPS \$(0.53) vs. Est. \$(0.65)

Financial news for NRX dated on 2015-11-04: NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin

Financial news for NRX dated on 2015-11-03: NephroGenex Reports \$5.5M Private Placement

Financial news for NRX dated on 2015-09-01: NephroGenex: A Significant Unmet Medical Need

Financial news for NRX dated on 2015-09-01: Benzinga's Top Initiations

Financial news for NRX dated on 2015-09-01: H.C. Wainwright Initiates Coverage on NephroGenex at Buy, Announces $$9.00\ PT$

Financial news for NRX dated on 2015-08-12: NephroGenex Reports Q2 Net Loss of 0.72/Share vs Loss of 0.56/Share Est.

Financial news for NRX dated on 2015-08-07: S-3 from NephroGenex Shows Registration for \$100M Mixed Securities Shelf Offering

Financial news for NRX dated on 2015-07-17: Morning Market Losers

Financial news for NRX dated on 2015-07-16: NephroGenex Prices 1.5M Shares, Warrants at Combined Price of \$5/Share, Warrants Have Exercise Price of \$6.25

Financial news for NRX dated on 2015-07-07: NephroGenex Amended S1 Shows Offer of 2.37M Shares

Financial news for NRX dated on 2015-06-25: Nephrogenix S-1 Shows Company Files To Offer \$15.0M In Common Stock

Financial news for NRX dated on 2015-05-13: NephroGenex Reports Q1 EPS \$(0.58) vs. Est. \$(0.62)

Financial news for NRX dated on 2015-03-27: NephroGenex Announces Data on Acute Kidney Injury at National Kidney Foundation 2015 Spring Clinical Meetings

Financial news for NRX dated on 2015-03-24: NephroGenex Reports Q4 -\$0.60 Vs Est -\$0.58

Financial news for NRX dated on 2015-03-23: MLV & Co. Initiates Coverage on NephroGenex at Buy, Announces \$20.00 PT

Financial news for NRX dated on 2015-01-08: Morning Market Gainers

Financial news for NRX dated on 2015-01-08: Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning

Financial news for NRX dated on 2015-01-08: Benzinga's Top #PreMarket Gainers

Financial news for NRX dated on 2015-01-08: UPDATE: NephroGenex Shares Rise 24% Premarket on European Medicines Agency Support of Phase 3 Program With Pyridorin

Financial news for NRX dated on 2015-01-07: Wednesday's After-Hours Movers

Financial news for NRX dated on 2015-01-07: European Medicines Agency Supports NephroGenex's Phase 3 Program With Pyridorin

Financial news for NRX dated on 2015-01-07: UPDATE: NephroGenex Shares Spike Higher After-Hours on Report of Positive EMA Advice

Financial news for NRX dated on 2015-01-07: Nephrogenex Says EMA Indicated Current Phase 3 Program Could Be Adequate For Marketing Authorization Application In Europe

Financial news for NRX dated on 2015-01-02: Stocks To Watch For January 2, 2015

Financial news for NRX dated on 2014-12-31: Mid-Afternoon Market Update: U.S. Stocks Turn Red; Tekmira Pharmaceuticals Shares Climb Following Clinical Study Update

Financial news for NRX dated on 2014-12-31: Mid-Day Gainers From New Year's Eve 2014: NephroGenex And Other Biopharma Stocks

Financial news for NRX dated on 2014-12-31: Mid-Day Market Update: Meadowbrook Insurance Shares Jump On Acquisition News; Crude Oil Drops Over 2%

Financial news for NRX dated on 2014-12-31: Mid-Morning Market Update: Markets Gain; Pacific Ethanol Reports Merger Deal With Aventine Renewable Energy

Financial news for NRX dated on 2014-12-31: Stocks Hitting 52-Week Highs

Financial news for NRX dated on 2014-12-31: UPDATE: NephroGenex Shares Rise 260% on Positive Kidney Treatment Data

Financial news for NRX dated on 2014-12-31: Morning Market Movers

Financial news for NRX dated on 2014-12-31: Biotech Stocks Make Big Moves In Final Days Of 2014

Financial news for NRX dated on 2014-12-31: Benzinga's Top #PreMarket Gainers

Financial news for NRX dated on 2014-12-31: NephroGenex Shares Rise 187% Premarket Following Announcement of Positive Results for QT Study of Pyridorin

Financial news for NRX dated on 2014-12-31: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for NRX dated on 2014-12-31: Must Watch Stocks for December 31, 2014

Financial news for NRX dated on 2014-12-30: NephroGenex Announces Positive Results for QT Study of Pyridorin

Financial news for NRX dated on 2014-12-30: NephroGenex Reports Positive Results for QT Study of Pyridorin

Financial news for NRX dated on 2014-08-11: Nephrogenex to Reach Agreement With FDA for Proposed PYR-311 Interim Analysis Plan By End of Q3; Will Continue to Enroll Patients In Phase 3 Pyridorin Trial, Half of the 600 Patients to be Enrolled By Q1 2015

Financial news for NRX dated on 2014-08-11: NephroGenex Reports Q2 EPS of \$(0.61) Which May Not Compare \$(0.24) Est

Financial news for NRX dated on 2014-06-18: NephroGenex Initiates Phase 3 Pyridorin

Financial news for NRX dated on 2014-05-21: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Financial news for NRX dated on 2014-05-14: NephroGenex Reports Q1 EPS of \$(0.37)

Financial news for NRX dated on 2014-04-01: Stocks Hitting 52-Week Lows

Financial news for NRX dated on 2014-03-25: Stocks Hitting 52-Week Lows

Financial news for NRX dated on 2014-02-11: Shares of NephroGenex Open for Trade at \$12.12 After Pricing at \$12/Share

Financial news for NRX dated on 2014-02-11: NephroGenex Shares Now Open for Quote, Expected to Open for Trade at 10:50AM EST; Priced 3.1M Shares at \$12/Share

Financial news for NRX dated on 2014-02-10: NephroGenex Prices 3.1M Share IPO at \$12/Share

Financial news for NRX dated on 2014-01-21: NephroGenex Prices IPO at \$12-\$14/Share